WUXI BIOLOGICS UNSP.ADR/2 (F:1FW1) — Market Cap & Net Worth
Market Cap & Net Worth: WUXI BIOLOGICS UNSP.ADR/2 (1FW1)
WUXI BIOLOGICS UNSP.ADR/2 (F:1FW1) has a market capitalization of $14.75 Billion (€12.62 Billion) as of June 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #1667 globally and #357 in its home market, demonstrating a -9.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying WUXI BIOLOGICS UNSP.ADR/2's stock price €7.20 by its total outstanding shares 2053636317 (2.05 Billion).
WUXI BIOLOGICS UNSP.ADR/2 Market Cap History: 2021 to 2026
WUXI BIOLOGICS UNSP.ADR/2's market capitalization history from 2021 to 2026. Data shows change from $46.41 Billion to $15.49 Billion (-18.81% CAGR).
WUXI BIOLOGICS UNSP.ADR/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how WUXI BIOLOGICS UNSP.ADR/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1FW1 by Market Capitalization
Companies near WUXI BIOLOGICS UNSP.ADR/2 in the global market cap rankings as of June 17, 2026.
Key companies related to WUXI BIOLOGICS UNSP.ADR/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
WUXI BIOLOGICS UNSP.ADR/2 Historical Marketcap From 2021 to 2026
Between 2021 and today, WUXI BIOLOGICS UNSP.ADR/2's market cap moved from $46.41 Billion to $ 15.49 Billion, with a yearly change of -18.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €15.49 Billion | -4.44% |
| 2025 | €16.21 Billion | +54.11% |
| 2024 | €10.52 Billion | -33.13% |
| 2023 | €15.73 Billion | -52.54% |
| 2022 | €33.13 Billion | -28.62% |
| 2021 | €46.41 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of WUXI BIOLOGICS UNSP.ADR/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.75 Billion USD |
| MoneyControl | $14.75 Billion USD |
| MarketWatch | $14.75 Billion USD |
| marketcap.company | $14.75 Billion USD |
| Reuters | $14.75 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About WUXI BIOLOGICS UNSP.ADR/2
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic disc… Read more